No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 2,151,646 | 2,106,051 | 2,461,317 | 2,726,485 | 2,784,878 | 3,037,312 | 3,074,505 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 103,931 | 79,768 | 161,880 | -91,947 | 43,806 | 134,996 | 158,793 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Asahi Kasei Corporation is a prominent Japanese enterprise operating globally in the manufacturing, processing, and distribution of a broad spectrum of products, primarily rooted in chemical science. Its diverse operations are strategically organized into three key business units: Material, Homes, and Health Care. Within the Material segment, the company produces a vast array of industrial and specialty chemicals, including foundational chemicals like caustic soda, nitric acid, and ammonia, alongside advanced intermediates such as acrylonitrile and styrene. This segment also encompasses a wide range of polymers, functional membranes, electronic and optical materials, and battery separators crucial for various industries. Furthermore, it offers high-performance fibers and textiles, such as cupro and nylon products, nonwoven fabrics, synthetic rubber, and elastomers. Consumer-oriented products like household items, cleaners, and packaging solutions, as well as electronic devices, also fall under this division. The Homes segment specializes in residential construction, providing a comprehensive suite of services that includes building houses and apartments, managing rental properties and condominiums, brokering used homes, and delivering remodeling solutions. It also extends financial services, such as mortgage financing and asset management, along with insurance products, supporting the entire homeowner journey. Lastly, the Health Care division focuses on developing and supplying pharmaceuticals and diagnostic reagents. It manufactures a variety of advanced medical equipment, including dialyzers, therapeutic apheresis systems, filters for biotherapeutics and virus removal, leukocyte reduction filters, and critical care devices like defibrillators and temperature management systems. Innovative technologies such as UVC LED products are also part of its offerings, contributing to advancements in health. Established in 1922, Asahi Kasei maintains its corporate headquarters in Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Asahi Kasei Corporation (3407.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Asahi Kasei Corporation is a prominent Japanese enterprise operating globally in the manufacturing, processing, and distribution of a broad spectrum of products, primarily rooted in chemical science. Its diverse operations are strategically organized into three key business units: Material, Homes, and Health Care. Within the Material segment, the company produces a vast array of industrial and specialty chemicals, including foundational chemicals like caustic soda, nitric acid, and ammonia, alongside advanced intermediates such as acrylonitrile and styrene. This segment also encompasses a wide range of polymers, functional membranes, electronic and optical materials, and battery separators crucial for various industries. Furthermore, it offers high-performance fibers and textiles, such as cupro and nylon products, nonwoven fabrics, synthetic rubber, and elastomers. Consumer-oriented products like household items, cleaners, and packaging solutions, as well as electronic devices, also fall under this division. The Homes segment specializes in residential construction, providing a comprehensive suite of services that includes building houses and apartments, managing rental properties and condominiums, brokering used homes, and delivering remodeling solutions. It also extends financial services, such as mortgage financing and asset management, along with insurance products, supporting the entire homeowner journey. Lastly, the Health Care division focuses on developing and supplying pharmaceuticals and diagnostic reagents. It manufactures a variety of advanced medical equipment, including dialyzers, therapeutic apheresis systems, filters for biotherapeutics and virus removal, leukocyte reduction filters, and critical care devices like defibrillators and temperature management systems. Innovative technologies such as UVC LED products are also part of its offerings, contributing to advancements in health. Established in 1922, Asahi Kasei maintains its corporate headquarters in Tokyo, Japan.
